Estrogen receptor (ER)

Similar documents
Estrogen receptor (ER)

Estrogen receptor (ER)

Assessment Run B HER2 IHC

SMH (Myosin, smooth muscle heavy chain)

Assessment Run GATA3

Assessment Run

Assessment Run B HER2 IHC

Assessment Run C1 2017

Lung Anaplastic Lymphoma Kinase (lu-alk)

Assessment Run C3 2018

Thyroid transcription factor-1 (TTF1) Assessment run

Carcinoembryonic antigen (CEA)

Sal-like protein 4 (SALL4)

Cytokeratin 19 (CK19)

Assessment Run NKX3.1 (NKX3.1)

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Epithelial cell-cell adhesion molecule (Ep-CAM)

Assessment Run CK19

HER2 ISH (BRISH or FISH)

Optimization of antibodies, selection, protocols and controls Breast tumours

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Assessment Run B HER-2

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital

External Quality Assessment of Breast Marker Analysis. NordiQC data

IHC Stainer platforms. Overview, pros and cons

NordiQC External Quality Assurance in Immunohistochemistry

Quality Assurance in Immunohistochemistry: Experiences from NordiQC

External Quality Assessment of melanocytic marker analyses NordiQC experience

Supplementary Online Content

NordiQC - update

Assessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver

10 years of NordiQC Why are 30% of labs still getting it wrong?

Nordic Immunohistochemical Quality Control

Immunohistochemical principles The technical test approach. Pre-analytical parametres

HPV/p16 Analyte Control

IDH1 R132H/ATRX Immunohistochemical validation

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

HistoCyte Laboratories Ltd

Single and Multiplex Immunohistochemistry

Results you can trust

The impact of proficiency testing on lab immunoassays

Immunotherapy in NSCLC Pathologist role

Product Introduction

Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies

Image analysis in IHC overview, considerations and applications

PD-L1 Analyte Control DR

Immunocytochemistry. Run 119/48. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

Milestones in Her 2 Testing

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers

Simultaneous de-waxing and standardisation of antigen retrieval in immunohistochemistry using commercially available equipment

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Diagnostic IHC in lung and pleura pathology

A National Quality Assurance program for breast immunohistochemistry: an Italian perspective

Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

Anti-PD-L1 antibody [28-8] ab205921

VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue

TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma

Bond Ready-to-Use Primary Antibody Progesterone Receptor (16)

Breast cancer diagnostic solutions Deliver diagnostic confidence

Lower 1D5 Sensitivity but Questionable Clinical Implications

The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia

Thermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System

Immunocytochemistry. Run 113/42. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use

07/06/2013. Commentary. The best way to achieve optimal treatment of today s patients is to ensure the availability of

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

PD-L1 IHC 22C3 pharmdx. SK tests for use with Autostainer Link 48 Table of Contents

Immunohistochemistry. Potential and challenges To be or not to be

Supplemental Data Table 1 Characteristics of the MHH BC cohort number percent cases histology IDBC ILBC others 6 3 pt status pt1

Molecular Probes Introducing 14 new probes

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

The PAX8 gene is a member of the paired-box family of

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC

Supplementary Appendix

Kristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

Novocastra Liquid Mouse Monoclonal Antibody Multi-Cytokeratin (4/5/6/8/10/13/18)

Immunocytochemistry. Results - Summary Graphs - Pass Rates Best Methods - Selected Images. Run 100. Assessment Dates: 3 rd - 22 nd January 2013

Supplementary Figure 1: Neuregulin 1 increases the growth of mammary organoids compared to EGF. (a) Mammary epithelial cells were freshly isolated,

Immunocytochemistry. Run 120/49. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Novocastra Liquid Mouse Monoclonal Antibody CD71

Speaking to you. This statement by Dr. Rodney T. Miller, Director of

PD-L1 and Immunotherapy of GI cancers: What do you need to know

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Classification of the unknown primary tumour: the primary IHC panel

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy

Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer

Immunohistochemical Expression Of Cytokeratin 8 And 18 In Breast Carcinoma.

Buffered solution containing hydrogen peroxide, detergent and mol/l sodium azide.

The Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast Carcinoma

NSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA

VENTANA PD-L1 (SP142) Assay

Welcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016

Transcription:

Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak to moderate 3. Breast carcinoma 0% Negative 4. Breast carcinoma 90-100% Moderate to strong 5. Breast carcinoma 40-50% Weak to strong 6. Breast carcinoma 60-80% Weak to moderate *ER-status and staining pattern as characterized by the NordiQC reference laboratories using the rmab clones EP1 and SP1. All tissues were fixed in 10% neutral buffered formalin for 24-48 hours and processed according to Yaziji et al. (1). Criteria for assessing ER staining results as optimal were: A moderate to strong, distinct nuclear staining reaction of virtually all columnar epithelial cells, basal squamous epithelial cells and most stromal cells (except endothelial and lymphoid cells) in the uterine cervix. An at least weak to moderate nuclear staining reaction of dispersed germinal centre macrophages and squamous epithelial cells of the tonsil. An at least weak to moderate distinct nuclear staining reaction in the appropriate proportion of the neoplastic cells in the breast carcinomas no. 4, 5 and 6. No nuclear staining reaction of neoplastic cells in the breast carcinoma no. 3. No more than a weak cytoplasmic staining reaction in cells with strong nuclear staining reaction. The staining reactions were classified as good if 10 % of the neoplastic cells in the breast carcinomas no. 4, 5 and 6 showed an at least weak nuclear staining reaction (but significantly less than the range of the reference laboratories), and an at least weak to moderate nuclear staining reaction in the majority of both the columnar and basal squamous epithelial cells in the uterine cervix. The staining reactions were classified as borderline if 1 % but < 10 % of the neoplastic cells showed a nuclear staining reaction in one or more of the breast carcinomas no. 4, 5 and 6. The staining reactions were classified as poor if a false negative or false positive staining reaction was seen in one or more of the breast carcinomas. Participation Number of laboratories registered for ER, B26 373 Number of laboratories returning slides 355 (95%) One laboratory returned a PR slide with an ER Ab. This laboratory was not included in the results below. Results 354 laboratories participated in this assessment. 245 of 354 (70%) achieved a sufficient mark (optimal or good). Table 1 summarizes antibodies (Abs) used and assessment marks (see page 2). The most frequent causes of insufficient staining results were: - Too low concentration of the primary Ab. - Insufficient HIER - too short efficient HIER time and/or use of a non-alkaline buffer. - Use of detection systems with low sensitivity. Conclusion The rabbit monoclonal antibody (rmab) clones SP1 and EP1 and the mouse monoclonal Ab (mab) clone 6F11 could all be used to provide an optimal result for ER. However, the seemed to be a more robust Ab and performed overall better than rmab clone EP1 and mab clone 6F11. The corresponding Ready-To-Use (RTU) system from Ventana/Roche provided the highest proportion of sufficient and optimal results. In this assessment, false negative staining reaction was the prominent feature of insufficient results. Uterine cervix is an appropriate positive tissue control for ER. Virtually all Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 1 of 8

stromal, columnar epithelial and squamous epithelial cells must show a moderate to strong and distinct nuclear staining reaction. Lymphocytes and endothelial cells must be negative. As a supplemental control to monitor the technical sensitivity of the assay, tonsil seems to be very valuable. In tonsil, an at least weak to moderate nuclear staining reaction of dispersed germinal centre macrophages and squamous epithelial cells must be seen. Table 1. Antibodies and assessment marks for ER, B26 Concentrated antibodies n Vendor Optimal Good Borderline Poor Suff. 1 Suff. OPS 2 mab clone 6F11 16 Leica/Novocastra 2 5 2 7 44% 100% rmab clone EP1 12 Dako/Agilent 2 4 4 2 50% 60% 20 6 2 1 1 Thermo Scientific Cell Marque Spring Bioscience Abcam Diagnostic Biosystems 14 7 4 5 70% 95% rmab clone S21-V 1 DB Biotech - - - 1 - - mab clone 1D5 1 Biocare Medical - - - 1 - - Ready-To-Use antibodies mab clone 1D5 IR/IS657 mab clones 1D5 + ER-2-123 SK310 mab clone 6F11 PA0009/PA0151 IR/IS084 1 Dako/Agilent - - - 1 - - 1 Dako/Agilent - - - 1 - - 11 Leica 1 1 2 7 18% - 32 Dako/Agilent 2 7 13 10 28% - IR/IS084 3 9 Dako/Agilent 2-5 2 22% - GA084 33 Dako/Agilent 4 18 6 5 67% 69% GA084 3 2 Dako/Agilent 1 1 - - - - 790-4324/5 193 Ventana/Roche 75 91 21 6 86% 85% 790-4324/5 3 1 Ventana/Roche - 1 - - - - 249R-1 KIT-0012 rmab SP1 M3011 MAD-000306QD RM-9101-R7 4 Cell Marque 2 1-1 - - 2 Maixin 1 - - 1 - - 1 Spring Biosystems - - - 1 - - 1 Master Diagnostica - - 1 - - - 3 Thermo Scientific 2 1 - - - - Total 354 108 137 58 51 - Proportion 31% 39% 16% 14% 70% 1) Proportion of sufficient stains (optimal or good). 2) Proportion of sufficient stains with optimal protocol settings only, see below. 3) RTU system used on a different platform than it was developed for. Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 2 of 8

Detailed analysis of ER, B26 The following protocol parameters were central to obtain optimal staining: Concentrated antibodies mab clone 6F11: Protocols with optimal results were based on heat induced epitope retrieval (HIER) using Cell Conditioning 1 (CC1, Ventana) (1/3)* or Novocastra Epitope Retrieval Solutions ph 6 (1/1) as retrieval buffer. The mab was typically diluted in the range of 1:25-1:50 using a 3-layer detection system. Using these protocol settings, 6 of 6 (100%) laboratories produced a sufficient staining result (optimal or good). * (number of optimal results/number of laboratories using this HIER buffer) rmab clone EP1: Protocols with optimal results were based on HIER using Target Retrieval Solution (TRS) ph 9 (3-in-1) (Dako) (1/7) or TRS High ph (Dako) (1/1) as retrieval buffer. The rmab was diluted in the range of 1:40-1:50 using a 3-layer detection system. Using these protocol settings, 3 of 5 (60%) laboratories produced a sufficient staining result. : Protocols with optimal results were all based on HIER using TRS ph 9 (Dako) (3/4), CC1 (Ventana) (6/10), Bond Epitope Retrieval Solution 2 (BERS2, Leica) (4/7) or Tris-EDTA ph 9 (1/4) as retrieval buffer. The rmab was typically diluted in the range of 1:25-1:100 depending on the total sensitivity of the protocol employed. Using these protocol settings, 18 of 19 (95%) laboratories produced a sufficient staining result. Table 2 summarizes the overall proportion of optimal staining results when using the three most frequently used concentrated Abs on the most commonly used IHC stainer platforms. Table 2. Optimal results for ER using concentrated antibodies on the main IHC systems* Concentrated antibodies Dako/Agilent Autostainer Dako/Agilent Omnis Ventana BenchMark XT / Ultra TRS ph 9.0 (3-in- 1) TRS ph 6.1 (3-in- 1) TRS High ph TRS Low ph CC1 ph 8.5 CC2 ph 6.0 Leica Bond III / Max BERS2 ph 9.0 BERS1 ph 6.0 mab clone - - 0/1** - 1/3-0/7 0/2 6F11 rmab clone 1/7-1/1-0/1-0/1 - EP1 (14%) rmab clone 6/10 4/7 0/1-3/4 - - - SP1 (60%) (57%) * Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective platforms. ** (number of optimal results/number of laboratories using this buffer) Ready-To-Use antibodies and corresponding systems mab clone 6F11, product. no. PA0009/PA0151, Leica/Novocastra, Bond III/Bond Max: One protocol with an optimal result was based on HIER using BERS2 20 min., 60 min. incubation of the primary Ab and Bond Polymer Refine Detection (DS9800) as detection system. Only one laboratory used these protocol settings (optimal or good). rmab clone EP1, product no. IR084/IS084, Dako Agilent, Autostainer+/Autostainer Link: Protocols with optimal results were based on HIER in PT-Link using TRS ph 9 (3-in-1) (efficient heating time 20-30 min. at 97-98 C), 20 min. incubation of the primary Ab and EnVision FLEX (K8000/K8002) with rabbit linker (K8009/K8019) as detection system. Using these protocol settings, 3 of 3 laboratories produced a sufficient staining result. 9 laboratories used product no IR084/IS084 on other platforms. These were not included in the description above. mab clone EP1, product no. GA084, Dako, Dako Omnis: Protocols with optimal results were typically based on HIER using TRS High ph (efficient heating time 30 min. at 97 C), 10-25 min. incubation of the primary Ab and Envision FLEX (GV800) as detection system. Using these protocol settings, 22 of 32 (69%) laboratories produced a sufficient staining result. 2 laboratories used product no. GA084 on other platforms. These were not included in the description above. Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 3 of 8

, product no. 790-4324/4325, Ventana, BenchMark XT, GX, ULTRA: Protocols with optimal results were typically based on HIER using CC1 (efficient heating time 32-64 min.), 16-40 min. incubation of the primary Ab and IView (760-091), UltraView (760-500) or OptiView (760-700) as detection system. Using these protocol settings, 153 of 179 (85%) laboratories produced a sufficient staining result. One laboratory used product no 790-4324/4325 on Dako Autostainer. This was not included in the description above. Table 3 summarizes the proportion of sufficient and optimal marks for the most commonly used RTU systems. The performance was evaluated both as true plug-and-play systems performed accordingly to the vendor recommendations and by laboratory modified systems changing basal protocol settings. Only protocols assays performed on the specific IHC platform are included. Table 3. Comparison of pass rates for vendor recommended and laboratory modified RTU protocols RTU systems Vendor recommended protocol settings* Laboratory modified protocol settings** Sufficient Optimal Sufficient Optimal Dako AS48 1/4 0/4 8/16 (50%) 2/16 (13%) IR084/IS084 Dako Omnis 18/27 (67%) 3/27 (11%) 4/6 (67%) 1/6 (17%) GA084 Leica Bond mab 6F11 0/4 0/4 2/7 (29%) 1/7 (14%) PA009/PA0151 VMS Ultra/XT/GX rmab SP1 790-4324/4325 33/37 (89%) 12/37 (32%) 133/156 (85%) 63/156 (40%) * Protocol settings recommended by vendor Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment. ** Significant modifications: retrieval method, retrieval duration and Ab incubation time altered >25%, detection kit. Only protocols performed on the specified vendor IHC stainer are included. Comments In this assessment a significant decrease in pass rate was seen (see Graph 1 below). The circulated material challenged the overall diagnostic sensitivity of the protocols on a higher level than in previous runs. Virtually all laboratories were able to demonstrate ER in the high-level ER expressing breast carcinoma (tissue core no. 4), in which 90-100% of the neoplastic cells were expected to be demonstrated. Demonstration of ER in the breast carcinoma no. 6, in which an at least weak nuclear staining reaction of 60% of the neoplastic cells was expected, was much more challenging and required a carefully calibrated protocol. In concordance with the previous NordiQC runs for ER, the prominent feature of an insufficient staining result was a too weak or false negative staining reaction. This pattern was seen in all of the insufficient results (109 of 109). No laboratories obtained a false positive staining reaction. The three most commonly used Abs both as concentrated formats and RTU systems were rmab clones SP1, used by 66% (235 of 354), EP1, used by 25% (88 of 354) and mab clone 6F11, used by 7% (27 of 354). The performed significantly better than both rmab clone EP1 and mab clone 6F11 with a total pass rate of 83% (195 of 235), 40% optimal. rmab clone EP1 obtained a total pass rate of 46% (41 of 88), 12% optimal, and mab clone 6F11 gave an overall pass rate of 33%, 11% optimal. 17% (60 of 354) of the participants used Abs as concentrated formats within laboratory developed (LD) assays. The three most commonly Abs, mab clone 6F11 and rmab clones EP1 and SP1 used in a LD assay could provide sufficient and optimal results on the main IHC platforms (Dako/Agilent, Leica and Ventana/Roche), see Tables 1 and 2. Irrespective of the clone applied, efficient HIER, preferable in an alkaline buffer, was a central protocol parameter for optimal results. When using HIER in a non-alkaline buffer, such as citrate ph 6, a pass rate of 22% (2 of 9) was seen, one of which was optimal. In comparison, HIER in an alkaline buffer provided a pass rate of 63% (32 of 51), 33% optimal. Using a 2- layer detection system a pass rate of 16% (3 of 19) was seen, 11% optimal. When using a 3-layer detection system, a pass rate of 76% (31 of 41) was seen, 39% optimal. Grouped together, the LD assays in this run provided a pass rate of 57 % (34 of 60). In addition, an important prerequisite for optimal performance seemed to be careful calibration of the primary Ab i.e., adjustment of the titer to the overall level of sensitivity of the IHC system. Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 4 of 8

Ready-To-Use (RTU) Abs were used by 83% (294 of 354) of the participants. 96% (282 of 294) of the laboratories used a complete RTU system including the pre-diluted primary Ab, specified ancillary reagents and the specific IHC stainer platform. The Ventana/Roche RTU system, based on the (790-4324/4325), was in this assessment the most widely used assay and gave an overall pass rate of 86%. Optimal results could be obtained both by the vendor recommended protocol settings (16 min. incubation of the primary Ab, HIER in CC1 for 64 min. and UltraView or iview as detection kit) and by laboratory modified protocols adjusting incubation time of the primary Ab, HIER time and detection system as shown in Table 3. Use of OptiView or UltraView with amplification as detection system was the most successful modification observed, used by 35 laboratories. 33 laboratories (94%) obtained a sufficient result. The most common modification observed was a shortened HIER time. 85 laboratories used HIER for <40 min and 81% (69 of 85) obtained a sufficient result. The Dako/Agilent RTU system IR084/IS084 for Autostainer based on the provided an overall pass rate of 28%. Four laboratories used the RTU as recommended by Dako, with one sufficient staining result. 16 laboratories modified the protocol with a pass rate of 50% (8 of 16). The most common modification observed was use of FLEX+ and rabbit linker, used by 14 laboratories. 8 laboratories (57%) obtained a sufficient result. The Dako/Agilent RTU system GA084 for Omnis, also based on rmab clone EP1, gave an overall pass rate of 67%. Sufficient results could be obtained both by the vendor recommended protocol and by laboratory modified protocols as shown in Table 3. Using protocols according to the recommendations provided by Dako (HIER in TRS High for 30 min., 10 min. incubation of the primary Ab with FLEX as detection system), a pass rate of 67% (18 of 27) was obtained. Laboratory modified protocol settings provided the same pass rate of 67%. The six modified protocols all increased incubation time of the primary Ab. The Leica RTU system PA009/PA0151 for BOND gave an overall pass rate of 18%. Sufficient results were only obtained by laboratory modified protocols settings using HIER in BERS2 for 20 min. as opposed to performing HIER in BERS1 for 20 min. as recommended by Leica. 12 laboratories used RTU assays on other platforms than the intended. 5 of 12 (42%) obtained a sufficient result (25% optimal). However, it must be emphasized, that the protocol must be meticulously validated by the end-users, when changing the systems to another platform than it was developed for. Performance history This was the nineteenth NordiQC assessment of ER. The proportion of sufficient results was significantly reduced compared to the latest run (see Graph 1). Graph 1. Participant numbers and pass rates for ER during 19 runs 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 39 32 25 52 Pass rate 14 17 12 22 24 37 64 20 37 46 33 111 75 51 61 85 100117133 178 204 216 248 234 37 32 29 29 306362357331 109 245 8 10 13 B1 B3 B5 B7 B8 B10B11B13B15B17B19B21B23B24B25B26 Insuff Suff The decrease of sufficient results can be caused by many factors. The circulated material challenged the diagnostic sensitivity of the Abs and protocols on a higher level than in the previous assessments, and might be the main reason for the low pass rate. Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 5 of 8

No obvious other cause to the decreased pass rate could be identified in the submitted data. A daily variation of the laboratory performance due to e.g. period since last maintenance, fading Abs or reagents, could be the reason for the different scores for similar protocol settings. Controls In concordance with previous NordiQC runs, uterine cervix was found to be an appropriate positive tissue control for ER staining: In optimal protocols, virtually all epithelial cells throughout the layers of the squamous epithelium and in the glands showed a moderate to strong and distinct nuclear staining reaction. In the stromal compartment, moderate to strong nuclear staining reaction was seen in most cells except endothelial and lymphatic cells. Tonsil was found to be highly recommendable as a tool to monitor the analytical sensitivity for the IHC demonstration of ER and was in fact superior to uterine cervix. It was observed, that dispersed germinal centre macrophages and squamous epithelial cells were distinctively demonstrated in virtually all protocols providing an optimal result. If the germinal centre macrophages were negative, a reduced proportion of ER positive cells were seen in the other tissues and a too weak or even false negative staining was seen in the breast carcinoma no. 5. Simultaneously, tonsil can be used as supplementary negative tissue control, as B-cells in mantle zones and within germinal centres must be negative. To validate the specificity of the IHC protocol further, an ER negative breast carcinoma must be included as primary negative tissue control, in which only remnants of normal epithelial and stromal cells are ER positive, serving as internal positive tissue control. Positive staining reaction of the stromal cells in breast tissue indicates that a highly sensitive protocol is being applied, whereas the sensitivity cannot be evaluated in normal epithelial cells in breast as they express high levels of ER. 1. Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG; Members of the Standardization Ad-Hoc Consensus Committee. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):513-20. PubMed PMID: 18931614. Fig. 1a Optimal ER staining of the uterine cervix using the rmab clone SP1 in an RTU format with optimal protocol settings. Virtually all squamous and columnar epithelial cells show a moderate to strong nuclear staining reaction. The majority of the stromal cells are demonstrated and only endothelial and lymphoid cells are negative. Also compare with Figs. 2a 4a, same protocol. Fig. 1b ER staining of the uterine cervix using an insufficient protocol - same field as in Fig. 1a. The proportion of positive stained squamous epithelial cells is significantly reduced. Also compare with Figs. 2b - 4b, same protocol. The protocol was based on the as an RTU with too short efficient HIER time and a 2-step polymer based detection system. Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 6 of 8

Fig. 2a Optimal ER staining of tonsil using same protocol settings as in Fig. 1a. A moderate to strong, distinct nuclear staining reaction is seen in the squamous epithelial cells and in dispersed germinal centre macrophages. Fig. 2b ER staining of tonsil using same protocol settings as in Fig. 1b. Only squamous epithelial cells demonstrate a faint staining reaction. All germinal centre cells are virtually negative. Fig. 3a Optimal ER staining of the breast ductal carcinoma no. 4 with 90-100% cells positive using same protocol as in Fig. 1a. Virtually all neoplastic cells show a strong, distinct nuclear staining reaction with only a weak cytoplasmic staining reaction. No background staining is seen. Fig. 3b ER staining of the breast ductal carcinoma no. 4 with expected 90-100% cells positive using same protocol as in Fig. 1b. The proportion of positive stained neoplastic cells are as expected, but the intensity is much weaker compared to Fig. 3b. Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 7 of 8

Fig. 4a Optimal ER staining of the breast ductal carcinoma no. 6 with 60-80% cells positive using same protocol as in Figs. 1a - 3a. The majority of neoplastic cells show a weak to moderate distinct nuclear staining reaction. No background staining is seen. Fig. 4b Insufficient ER staining of the breast ductal carcinoma no. 6 with expected 60-80% cells positive using same protocol as in Figs. 1b - 3b. The carcinoma is virtually negative. The intensity and proportion of cells demonstrated is significantly reduced compared to the level expected. HLK/LE/MV/RR 08.12.2018 Nordic Immunohistochemical Quality Control, ER run B26 2018 Page 8 of 8